Drug resistant tuberculosis in Poland in 2008. Comparison with results from studies in WHO programs from 1997-2004
Journal Title: Postępy Nauk Medycznych - Year 2011, Vol 24, Issue 10
Abstract
Introduction. The knowledge of the prevalence of drug resistant tuberculosis in the population is important information about the epidemiology of the disease in the country. WHO has published three reports on the global incidence of primary and acquired resistance tuberculosis in 76 countries.In Poland, the incidences of drug-resistant tuberculosis have been monitored since the early years of chemotherapy. In the period from 1997 to 2008 were four prospective studies covering the whole country.The aim of this study was to determine the prevalence primary and acquired drug resistance of M. tuberculosis strains isolated from patients in Poland in 2008, compared with the results obtained in previous studies (1997, 2000, 2004).Material and methods. The material for the work was taken from 4365 tuberculosis patients excreting susceptible and drug resistant bacilli during the 12-months from 1st January to 31st December 2008. Data about patients were collected based on the results of routine diagnostic tests carried out in tuberculosis laboratories. Division by age group, verification and analysis of data was performed according to WHO recommendations. Drug susceptibility testing was performed on solid medium (L-J) by proportion method and liquid medium using the Bactec MGIT 960 system.Results. In this study we were included 4314 patients with tuberculosis (86.1% new and 13.9% treated cases). Among 3715 studied untreated patients 165 (4.4%) excreting drug resistant bacilli. In this group mono-resistance strains was dominated (112 patients – 3%). MDR-TB was found in 18 (0.5%) patients and bacilli resistant to 4 drugs in 13 patients (0.3%).Among previously treated patients 79 (13.2%) excreting drug resistant bacilli. MDR-TB was found in 34 patients (5.7%), bacilli resistant to 3 drugs SM+INH+RMP (12 patients – 2%) and 4 drugs M+INH+RMP+EMB (11 patients – 1.8%).Conclusions. Among untreated patients 165 (4.4%) excreting drug resistant bacilli, in previously treated patients 79 (12.2%) excreting drug resistant bacilli MDR-TB was more often in untreated (5.7%) than previously treated patients (0.5%).
Authors and Affiliations
Anna Zabost, Magdalena Klatt, Agnieszka Napiórkowska, Sylwia Brzezińska, Monika Kozińska, Dagmara Borkowska, Zofia Zwolska, Ewa Augustynowicz-Kopeć
Keywords
Related Articles
- EP ID EP54038
- DOI -
- Views 172
- Downloads 0
Outcome of urinary incontinence treatment with artificial urinary sphincter (AUS) implantation
Introduction. One of the well documented method of urinary incontinence (UI) treatment due to an incompetent urinary sphincter mechanism is Implantation of artificial urinary sphincter (AUS). It can be used in man and fe...
Ocena zależności między stężeniem adiponektyny i składowymi zespołu metabolicznego u dzieci i młodzieży z otyłością prostą
Wstęp. Adiponektyna jest białkiem tkanki tłuszczowej pełniącym wiele funkcji i odgrywającym istotną rolę w patogenezie zespołu metabolicznego u dzieci.Cel pracy. Ocena zależności między stężeniem adiponektyny i zespołem...
Endovascular treatment of diabetic foot syndrome
<b>Introduction.</b> Diabetic foot syndrome is an infection and/or ulceration and/or destruction of deep tissue foot (skin, muscle, bone) caused by damage of peripheral nerves or limb arteries...
Lymphangioleiomyomatosis
Lympangioleiomyomatosis (LAM) is a rare lung disease that affects almost exclusively women, primarily in their reproductive years. It is characterized by proliferation of abnormal smooth muscle-like cells (LAM cells), wh...
Fibromyalgia – a disease or a pain syndrome?
Fibromyalgia is painful, noninflammatory disease characterized by widespread pain and diffuse tenderness. The main symptoms are accompanied by fatigue, sleep disturbances, headaches and memory impairment. Etiology of fib...